MRRS adds "Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).

Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.

This report covers all gastrointestinal disorders, but there is a particular focus on three key diseases: gastroesophageal reflux disease, irritable bowel syndrome and inflammatory bowel disease. The global gastrointestinal market was valued at $35.7 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs) and tumor necrosis factor (TNF)-α inhibitors generate the largest revenues and continue to retain commercial prominence. Key drivers of market growth will be the uptake of recently approved premium products, rising prevalence, and promising late-stage products, including a number of biologic therapies that are expected to be highly valuable.

Table of Contents
3 Key Marketed Products 23
3.1 Overview 23
3.2 Humira (adalimumab) 24
3.3 Remicade (infliximab) 26
3.4 Soliris (eculizumab) 28
3.5 Tysabri (natalizumab) 29
3.6 Nexium (esomeprazole magnesium) 31
3.7 Entyvio (vedolizumab) 33
3.8 Protonix (pantoprazole) 35
3.9 Ocaliva (obeticholic acid) 37
3.10 Dexilant (dexlansoprazole) 38
3.11 Amitiza (lubiprostone) 40
3.12 Takecab (vonoprazan) 41
3.13 Linzess (linaclotide) 43
4 Pipeline Landscape Assessment 45
4.1 Overview 45
4.2 Molecule Types in the Pipeline 47
4.3 Molecular Targets in the Pipeline 48
4.4 Clinical Trials Landscape 50
4.4.1 Clinical Trial Failure Rates 51
4.4.2 Clinical Trial Duration 54
4.4.3 Clinical Trial Size 58
4.4.4 Cumulative Clinical Trial Size 61
4.5 Late-Stage Drugs of the Developmental Pipeline 64
4.5.1 RPC1063 (ozanimod) - Celgene 64
4.5.2 GED-0301 (mongersen) - Celgene 65
4.5.3 Stelara (ustekinumab) - Johnson & Johnson 66
4.5.4 Victoza (liraglutide) - Novo Nordisk 68
4.5.5 Plecanatide - Synergy Pharmaceuticals 69
4.6 Conclusion 70......

List of Tables and Figures 
Table 1: Gastrointestinal Disorders, EU5 and US, Epidemiology of Gastrointestinal Disorders, 2015 16
Table 2: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Humira, 2016 24
Table 3: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Remicade, 2016 26
Table 4: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Soliris, 2016 28
Table 5: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Tysabri, 2016 29
Table 6: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Nexium, 2016 32
Table 7: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Entyvio, 2016 33
Table 8: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Protonix, 2016 35
Table 9: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Ocaliva, 2016 37
Table 10: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Dexilant, 2016 38
Table 11: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Amitiza, 2016 40
Table 12: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Takecab, 2016 42.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-gastrointestinal-drug-market-to-2022-pipeline-characterized-by-emerging-biologic-therapies-while-tnf-inhibitors-and-ppis-continue-to-dominate-therapy-landscape

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/